Ambulatory Care Pharmacy Specialty Review Course for Recertification

** Materials for this course will be released on 06/26/2019 **

Ambulatory Care Pharmacy Specialty Review Course for Recertification + RECERT EXAM Package
(Cert # L199264)

Teaser: This online course will help you earn BCACP recertification credit. With this course, you will get comprehensive, practical guidance, with a variety of complex cases, including references for further study.

ACPE Numbers: Various – see listing below
Pre-Sale Date: 05/08/2019
Content Release Date: 06/26/2019
Expiration Date: 12/17/2019
Activity Type: Application-based
CE Credits: 26.00 (BPS and ACPE)
Activity Fee: $475 (ASHP member); $675 (non-member)

Accreditation for Pharmacists
The American College of Clinical Pharmacy and American Society of Health-System Pharmacists are accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.

These activities were recorded during a live educational event on May 2-4, 2019 in Minneapolis, Minnesota. Learners who claimed credit for the live activities should not claim credit for these home study activities.

Target Audience
These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in ambulatory care pharmacy.

Activity Overview
This course is intended for BCACPs in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS) to provide an overview of recent standards and guidelines that specialists should be familiar with in practice. The course uses a case-based approach to discuss patient care issues. In this series, faculty will:

- Review pertinent clinical topics and practice skills
- List valuable resources for further self-study

This online course consists of 21 activities (see table below) and provides up to 26.00 hours of continuing pharmacy education credit and/or recertification credit.

Recertification Credit*
Board certified pharmacists are eligible to receive up to 26 hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

This course is not intended for those preparing to take the BPS Ambulatory Care Pharmacy Specialty Examination for Certification. To prepare for the examination, please see courses here http://elearning.ashp.org/catalog/amb-care-review:
These activities are part of the ASHP and ACCP professional development program for BCACP recertification approved by the BPS.

* Please note: Review Course for Recertification may only be completed for recertification credit up to two times, in nonconsecutive years, during the 7-year recertification cycle.

<table>
<thead>
<tr>
<th>Learning Activity</th>
<th>ACPE Number</th>
<th>Credit Hours</th>
<th>*Assessment Pass Point</th>
</tr>
</thead>
<tbody>
<tr>
<td>Practices and Processes of Care</td>
<td>0217-9999-19-049-H04-P</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Communication Strategies in Pharmacy</td>
<td>0217-9999-19-050-H04-P</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Developing a Clinical Practice</td>
<td>0217-9999-19-051-H04-P</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Managing a Clinical Practice</td>
<td>0217-9999-19-052-H04-P</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td><strong>Group 1 Assessment</strong></td>
<td></td>
<td><strong>4.00</strong></td>
<td></td>
</tr>
<tr>
<td>Cardiology I</td>
<td>0217-9999-19-053-H01-P</td>
<td>1.5</td>
<td>TBD</td>
</tr>
<tr>
<td>Cardiology II</td>
<td>0217-9999-19-054-H01-P</td>
<td>1.5</td>
<td>TBD</td>
</tr>
<tr>
<td>Genitourinary, Electrolytes, and Nutritional Deficiencies/Supplementation in Older Adults</td>
<td>0217-9999-19-055-H01-P</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td><strong>Group 2 Assessment</strong></td>
<td></td>
<td><strong>4.00</strong></td>
<td></td>
</tr>
<tr>
<td>Trial Design and Biostatistics</td>
<td>0217-9999-19-056-H04-P</td>
<td>2.5</td>
<td>TBD</td>
</tr>
<tr>
<td>Pulmonary Disorders</td>
<td>0217-9999-19-057-H01-P</td>
<td>1.5</td>
<td></td>
</tr>
<tr>
<td><strong>Group 3 Assessment</strong></td>
<td></td>
<td><strong>4.00</strong></td>
<td></td>
</tr>
<tr>
<td>Diabetes Mellitus</td>
<td>0217-9999-19-058-H01-P</td>
<td>1.5</td>
<td>TBD</td>
</tr>
<tr>
<td>Endocrine Disorders</td>
<td>0217-9999-19-059-H01-P</td>
<td>1.5</td>
<td>TBD</td>
</tr>
<tr>
<td>Obstetrics/Gynecology</td>
<td>0217-9999-19-060-H01-P</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td><strong>Group 4 Assessment</strong></td>
<td></td>
<td><strong>4.00</strong></td>
<td></td>
</tr>
<tr>
<td>Psychiatric Disorders</td>
<td>0217-9999-19-061-H01-P</td>
<td>1.5</td>
<td>TBD</td>
</tr>
<tr>
<td>Neurology</td>
<td>0217-9999-19-062-H01-P</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal Disorders</td>
<td>0217-9999-19-063-H01-P</td>
<td>1.5</td>
<td></td>
</tr>
<tr>
<td><strong>Group 5 Assessment</strong></td>
<td></td>
<td><strong>4.00</strong></td>
<td></td>
</tr>
<tr>
<td>Infectious Diseases I</td>
<td>0217-9999-19-064-H01-P</td>
<td>1</td>
<td>TBD</td>
</tr>
<tr>
<td>Infectious Diseases II</td>
<td>0217-9999-19-065-H01-P</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Nephrology</td>
<td>0217-9999-19-066-H01-P</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Bone/Joint and Rheumatology</td>
<td>0217-9999-19-067-H01-P</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td><strong>Group 6 Assessment</strong></td>
<td></td>
<td><strong>4.00</strong></td>
<td></td>
</tr>
<tr>
<td>Dermatologic and Eyes, Ears, Nose, and Throat, and Immunologic Disorders - Module 7A</td>
<td>0217-9999-19-068-H01-P</td>
<td>1</td>
<td>TBD</td>
</tr>
<tr>
<td>Policy, Practice, and Regulatory Issues - Module 7B</td>
<td>0217-9999-19-069-H04-P</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td><strong>Group 7 Assessment</strong></td>
<td></td>
<td><strong>2.00</strong></td>
<td></td>
</tr>
</tbody>
</table>
**Learning Objectives**
After participating in this CPE activity, leaners should be able to:

**Practices and Processes of Care**
ACPE # 0217-9999-19-049-H04-P

- Define a pharmacist’s scope of practice in ambulatory care pharmacy practice.
- Construct a collaborative practice agreement, protocol, etc., that is in accordance with legal and regulatory requirements.
- Compare and contrast the coding and billing for immunizations under Medicare Part B and Part D.
- Describe different types of patient care services or practice models provided by a pharmacist within an ambulatory practice.
- Apply tools and resources to detect, classify, report, analyze, and reduce preventable and non-preventable adverse drug events.
- Formulate a plan to ensure patient access to medications by facilitating the use of prescription drug plans and other resources.
- Use formulary management activities to improve the prescribing of safe, effective, and affordable treatments in an organization.
- Describe the regulatory requirements applicable to pharmacy services using point-of-care testing.

**Communication Strategies in Pharmacy**
ACPE # 0217-9999-19-050-H04-P

- Use strategies that develop patient rapport, foster trust, and effectively and efficiently obtain accurate, comprehensive histories, despite potential barriers in communication.
- Use assessments of patients’ knowledge, health literacy, self-management skills, health beliefs, and attitudes toward medications to tailor educational interventions that will improve adherence and self-efficacy.
- Communicate patient care activities and medication-related information effectively to other health care professionals verbally and in writing through the medical record.
- Discuss factors and methods used to assess and select appropriate written educational materials intended for the general public.
- Describe how to serve as a patient advocate on medication-related issues within and outside the health care system.

**Developing a Clinical Practice**
ACPE # 0217-9999-19-051-H04-P

- Perform an internal and external environmental scan for planning sustainable ambulatory clinical patient care service(s).
- Create a formal service proposal or business plan with the key elements identified as important to your organization.
- Develop a pro forma statement that financially supports your program within a business plan.
- Incorporate the seven P’s of marketing into a marketing plan for an ambulatory clinical service(s).
- Identify and perform five clinic operational activities before opening a clinic, including developing an optimal workflow process for your services.
- Develop and evaluate an effective set of clinic policies and procedures for an ambulatory clinic.

**Managing a Clinical Practice**
ACPE # 0217-9999-19-052-H04-P

- List three critical clinic functions for your clinic to assess and review on an annual basis to sustain a top-level practice.
- Develop a robust quality assessment program for your clinical service using the balanced scorecard.
- Analyze sources of quality measures important to your organization, and select the measures important to your practice site or patient population.
- Develop a credentialing and privileging process to ensure the competency of pharmacists providing direct patient care in your clinic setting.
• Differentiate pharmacist billing opportunities between a hospital-based clinic, physician office, and community pharmacy.
• Develop a proposal for pharmacists at your clinic site to participate in the range of current Medicare billing opportunities that will sustain the service for the next several years.
• Describe how pharmacist services in your setting may be incorporated into the Medicare Part B Quality Payment Program.

Cardiology I
ACPE # 0217-9999-19-053-H01-P
• Formulate appropriate oral anticoagulant treatment strategies for patients who develop venous thromboembolism (VTE) (deep venous thrombosis or pulmonary embolism) consistent with available consensus panel guidelines, recent U.S. Food and Drug Administration approvals, and randomized clinical trials.
• Describe key differences in onset of action, dosing, administration, absorption, effects on common coagulation tests, and drug interactions between dabigatran, rivaroxaban, apixaban, edoxaban, and warfarin in the management of nonvalvular atrial fibrillation (NVAF) and treatment and prevention of VTE.
• Develop a comprehensive education and monitoring plan for patients receiving oral anticoagulants for treatment and prevention of VTE, stroke prevention in NVAF, and stroke prevention associated with mechanical heart valves.
• Develop patient-specific, guideline-driven treatment, monitoring, and follow-up plans for patients with heart failure (HF).
• Develop patient-specific, guideline-driven treatment, monitoring, and follow-up plans for rate and pharmacologic rhythm control in a patient with atrial fibrillation (AF) and and ventricular tachycardia.
• Identify treatment goals, common adverse effects, clinically important drug interactions, monitoring, and REMS (Risk Evaluation and Mitigation Strategies) requirements for oral pharmacotherapy of pulmonary arterial hypertension.

Cardiology II
ACPE # 0217-9999-19-054-H01-P
• Recommend regimens for primary and secondary prevention of coronary heart disease (CHD) events according to current guidelines and performance measures.
• Calculate a patient’s initial 10-year risk for an atherosclerotic cardiovascular disease (ASCVD) event by using the 2013 Pooled Cohort Equation.
• Formulate an appropriate antiplatelet regimen after percutaneous coronary intervention according to current guidelines and product labeling for P2Y12 inhibitors and protease-activated receptor (PAR-1) antagonists.
• Recommend an appropriate time frame for discontinuing antiplatelet medications for surgical procedures.
• Apply an understanding of the mechanism of action and effects of antihypertensive medications to construct an appropriate pharmacologic and therapeutic monitoring plan for a patient with hypertension (HTN).
• Design an evidence-based HTN medication regimen according to comorbid conditions (e.g., chronic kidney disease [CKD], diabetes mellitus, CHD) and for patients who require combination antihypertensive therapy to achieve their blood pressure goals.
• Integrate an understanding of the mechanism of action and effects of lipid medications to select an appropriate pharmacologic and therapeutic monitoring plan for efficacy and safety.
• Create an evidence-based lipid-lowering medication regimen for primary and secondary prevention and for patients with dyslipidemia and comorbid conditions (e.g., peripheral arterial disease [PAD], CKD, potential drug interactions, chronic elevation in creatine kinase).
• Develop an evidence-based treatment strategy for patients with peripheral arterial disease.
• Recommend an evidence-based medication regimen for secondary prevention of stroke and transient ischemic attack (TIA).
Genitourinary, Electrolytes, and Nutritional Deficiencies/Supplementation in Older Adults
ACPE # 0217-9999-19-055-H01-P

- Describe the pathophysiology and clinical signs/ symptoms of benign prostatic hyperplasia (BPH), urinary incontinence, and erectile dysfunction (ED).
- Identify common electrolyte abnormalities and nutritional deficiencies that occur in ambulatory older adults.
- Evaluate and manage drug-induced causes of BPH, urinary incontinence, ED, hypokalemia, hyperkalemia, and hyponatremia in ambulatory older adults.
- Compare and contrast pharmacologic interventions for BPH, urinary incontinence, ED, hypovitaminosis D, vitamin B12 deficiency, hyperkalemia, hypokalemia, and calcium supplementation.
- Formulate treatment strategies for BPH, urinary incontinence, ED, hypovitaminosis D, vitamin B12 deficiency, hyperkalemia, and hypokalemia using patient-specific information.
- Evaluate the risk-benefit of multivitamin supplementation and the risk-benefit of antioxidant plus zinc supplementation for macular degeneration.

Trial Design and Biostatistics
ACPE # 0217-9999-19-056-H04-P

- Describe hypothesis testing, and state the meaning of and distinguish between p values and confidence intervals.
- Define, compare, and contrast the concepts of internal and external validity, bias, and confounding in trial design. Select strategies to eliminate or control for bias and improve internal and external validity.
- Compare and contrast the advantages and disadvantages of various study designs (e.g., prospective, retrospective, case-control, cohort, cross-sectional, randomized controlled clinical trials, systematic review, meta-analysis).
- Discuss the differences between causation and association.
- Describe the strengths and limitations of different types of measures of central tendency (mean, median, and mode) and data spread (standard deviation, standard error of the mean, range, and inter-quartile range).
- Determine why a statistical test is appropriate or not appropriate, given the sample distribution, data type, and study design. Interpret statistical significance for results from commonly used statistical tests.
- Define and evaluate odds ratio, risk/incidence rate, relative risk, number needed to treat, number needed to harm, and other risk estimates.
- Define and calculate terms such as true positive, false positive, true negative, false negative, sensitivity, specificity, positive predictive value, negative predictive value, positive likelihood ratio, and negative likelihood ratio.

Pulmonary Disorders
ACPE # 0217-9999-19-057-H01-P

- Classify, assess, control, select, and monitor appropriate treatment for pediatric and adult patients with asthma, adult patients with chronic obstructive pulmonary disease (COPD), and adult patients with obstructive sleep apnea (OSA), depending on patient-specific factors.
- Educate patients about their therapy for asthma, COPD, OSA, and smoking cessation, including the proper use of inhalers, holding chambers, positive airway pressure machines, and medications.
- Select and monitor appropriate pharmacotherapy, and provide behavioral counseling, to assist a patient in quitting smoking.
- Discuss public health, practice management, and patient advocacy issues as they pertain to asthma, COPD, OSA, and smoking cessation.

Diabetes Mellitus
ACPE # 0217-9999-19-058-H01-P

- Identify differences between prediabetes, type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), and gestational diabetes mellitus, including differences in diagnostic criteria and clinical presentation.
- Describe the pathophysiology of T1DM and T2DM.
- Compare agents used in the treatment of diabetes mellitus (DM), including their mechanisms of action, adverse effects, contraindications, advantages, and disadvantages for each agent discussed.
- Select appropriate insulin regimens for patients on the basis of desired onset, peak, and duration of insulin effects.
- Individualize a comprehensive glycemic treatment and monitoring plan for a patient with prediabetes, DM, and GDM.
Discuss appropriate blood pressure and lipid management for patients with DM.
Discuss the acute and chronic complications associated with DM and strategies to prevent or slow its progression.

Endocrine Disorders
ACPE # 0217-9999-19-059-H01-P
- Identify the most vulnerable patient populations receiving thyroid hormone replacement and explain the importance of consistent levothyroxine replacement for these patients. In addition, identify appropriate thyroid hormone replacement therapy dosing strategies for all patients with hypothyroidism.
- Discuss the pharmacotherapy of hyperthyroidism, including the advantages and disadvantages of antithyroid drugs versus radioactive iodine and surgery.
- Recommend appropriate patient-specific pharmacotherapy for the treatment of polycystic ovary syndrome.
- Medically manage a patient presenting with hyperprolactinemia. In addition, describe the typical differences in presentation of men versus women with prolactin-secreting tumors.
- Compare and contrast the available weight-loss medications with respect to mechanism of action, efficacy, and adverse effects, and design a patient-specific treatment plan for a patient who wishes to lose weight.
- Compare and contrast the role of drug therapy, transsphenoidal surgery, and radiation therapy for a patient with a diagnosis of acromegaly, and design a patient-specific pharmacologic treatment and monitoring plan.
- Describe the typical clinical features of patients with growth hormone deficiency, and design an appropriate pharmacologic treatment and monitoring plan on the basis of patient-specific factors.
- Recognize the clinical presentation and treatment of a patient with adrenal insufficiency.
- Identify indications when patients with Cushing syndrome would be candidates for pharmacologic treatment.
- List symptoms of hyperaldosteronism, and recommend appropriate drug therapy for its treatment.
- Compare the safety, efficacy, and routes of administration of available testosterone (T) replacement products. In addition, list appropriate monitoring guidelines for a man with hypogonadism receiving T-replacement therapy.

Obstetrics/Gynecology
ACPE # 0217-9999-19-060-H01-P
- Recommend therapy for contraception, infertility, menstrual disorders, endometriosis, and symptoms of menopause on the basis of patient-specific information.
- Recommend appropriate treatment for common acute and chronic conditions in pregnancy and lactation.
- Develop patient education regarding medication use during pregnancy and lactation, contraception, infertility, menstrual disorders, endometriosis, and postmenopausal therapy.
- Identify additional resources for health care providers and patients on contraception, infertility, pregnancy and lactation, menstrual disorders, endometriosis, and postmenopausal therapy.

Psychiatric Disorders
ACPE # 0217-9999-19-061-H01-P
- Analyze the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria, etiology, risk factors, and disease course for the anxiety disorders, sleep disorders, major depression, bipolar disorder, attention-deficit/hyperactivity disorder, and schizophrenia.
- Apply a working knowledge of common drug and nondrug therapies for the psychiatric disorders, including drug, dose, frequency, adverse effects, drug interactions, and monitoring parameters.
- Develop appropriate initial treatment plans and be able to modify therapy based on response and tolerability of medications for the psychiatric disorders described.
- Assess treatment regimens for significant drug interactions and appropriateness of therapy, including use of polytherapy.

Neurology
ACPE # 0217-9999-19-062-H01-P
- Given a patient case, identify seizure type(s), and select an appropriate antiepileptic drug (AED) regimen for the patient with epilepsy.
- Identify common adverse effects and drug interactions for first- and second-generation AEDs.
- Describe the mechanism of action of a given AED regimen.
• Recommend an appropriate pharmacologic therapy for a patient with episodic or chronic migraine headache.
• Select a treatment option and recommend appropriate management of disease modifying therapy for a patient with multiple sclerosis.
• Formulate a treatment plan for a patient with Parkinson disease.
• Evaluate for the appropriateness of initiating/continuing chronic opioid therapy in a patient with chronic pain.

Gastrointestinal Disorders
ACPE # 0217-9999-19-063-H01-P
• Evaluate and apply national guideline–based treatment strategies for GI disorders.
• Assess the benefits and risks of drug therapy for patients with GI disorders.
• Recommend appropriate nonpharmacologic and pharmacologic interventions for the management of GI disorders.
• Develop and implement a patient-specific comprehensive therapeutic plan for the management of GI disorders.
• Provide drug-related patient education and counseling for pharmacologic therapies used in the management of GI disorders.

Infectious Diseases I
ACPE # 0217-9999-19-064-H01-P
• Design appropriate treatment regimens for patient with sexually transmitted diseases.
• Describe routes of HIV transmission and current screening guidelines.
• Explain the mechanisms of action of antiretroviral agents and commonly encountered adverse effects.
• Formulate treatment strategies for the management of HIV and commonly encountered opportunistic infections.
• Select appropriate ancillary medications and immunizations as needed for the management of HIV infection and its associated morbidities.
• Explain the epidemiology of influenza and herpesviruses, and formulate appropriate strategies for treatment of infection.
• Explain the risk factors for superficial and invasive fungal infections, and design corresponding treatment regimens.
• Identify and manage the drug interactions associated with anti-infective medications.

Infectious Diseases II
ACPE # 0217-9999-19-065-H01-P
• Design appropriate pharmacologic and nonpharmacologic treatment regimens for various patient populations with urinary tract infections, prostatitis, community-acquired pneumonia, sinusitis, pharyngitis, otitis media, skin and soft tissue infections, tuberculosis, ophthalmic infections, bone and joint infections, tick-borne infections, infective endocarditis, central nervous system infections, antibiotic prophylaxis, infectious diarrhea, and Clostridium difficile infections.
• Identify risk factors and clinical circumstances for antimicrobial resistance.
• Design an antimicrobial therapeutic regimen to treat resistant infections and prevent future development.
• Apply evidence-based medicine and patient-specific factors to design antimicrobial regimens that are appropriate and cost-effective for the patient.

Nephrology
ACPE # 0217-9999-19-066-H01-P
• Identify a patient at risk of, or presenting with, acute kidney injury, and formulate an appropriate recommendation.
• Identify a patient at risk of, or presenting with, drug-induced kidney disease, and formulate an appropriate recommendation.
• Compare and contrast the available methods to assess kidney function. Using appropriate data, assess kidney function in a patient.
• Formulate an evidence-based treatment plan for managing the most common medical problems in patients with chronic kidney disease (CKD), including anemia and CKD-related mineral and bone disorder.
• Construct a treatment plan to slow the progression of CKD in patients with hypertension and diabetes.
• Describe the pharmacokinetic effects of peritoneal and hemodialysis on drug disposition.
• List the most common nephrolithiasis prevention measures and treatment options.
• List the multidisciplinary dialysis team members.
• Describe Medicare Part B policies related to endstage renal disease (ESRD) and dialysis care (i.e., ESRD Prospective Payment System, Quality Incentive Program, Conditions for Coverage).
• Describe the Centers for Medicare & Medicaid Services (CMS) Comprehensive ESRD Care Model (CEC).
• Explain relevant Medicare Part D policies and issues for patients with ESRD.

Bone/Joint and Rheumatology
ACPE # 0217-9999-19-067-H01-P
• Systematically identify patients to screen for osteoporosis and use the screening results to guide the decision on how to treat the patient.
• Use a STEPS-wise approach (safety, tolerability, efficacy, preference [pearls], simplicity) for comparing, recommending, and justifying a drug therapy regimen for osteoporosis.
• Identify appropriate health maintenance interventions when caring for a patient receiving biologic and synthetic disease-modifying antirheumatic drug (DMARD) therapy.
• Select the most appropriate treatment regimen for psoriatic arthritis on the basis of patient limitations because of the disease.
• Create an algorithm or a stepwise approach to minimize pain and maximize functionality in patients with osteoarthritis.
• Choose a drug therapy for treating fibromyalgia syndrome, based on drug efficacy and a patient’s comorbid conditions.
• Select follow-up screenings or laboratory tests at correct intervals for patients with systemic lupus erythematos treated with hydroxychloroquine.
• Formulate a care plan to help patients decrease their uric acid concentrations, gout symptoms, and gouty attacks by using nonpharmacologic and pharmacologic interventions.

Dermatologic and Eyes, Ears, Nose, and Throat, and Immunologic Disorders
ACPE # 0217-9999-19-068-H01-P
• Evaluate antioxidant and multivitamin supplements for components and is consistent with the AREDS (Age-Related Eye Disease Study) formulation for preventing the progression of macular degeneration.
• Formulate an ophthalmologic drug therapy regimen for a patient that will decrease the patient’s elevated intraocular pressures using agents that work synergistically (increased aqueous outflow and decreased production).
• Create criteria to evaluate dry eye symptom treatment beyond traditional artificial tears.
• Evaluate a medication profile to determine whether the signs and symptoms of vertigo are medication induced or a component of organic disease.
• Construct an individualized pharmacy care plan for a patient with allergic rhinitis who has received no relief from intranasal corticosteroids.
• Discuss the risks and benefits of agents used in addition to nonsedating histamine-1 blockers/ antagonists for the treatment of urticaria.
• Recommend appropriate treatments for patients receiving injectable medications for the treatment and/or prevention of angioedema.
• Determine how patients with acne should initiate, switch, or modify topical or oral therapeutic agents using a treatment algorithm.
• Educate a patient using isotretinoin about therapy and the various monitoring variables that will ensure drug safety and efficacy.
• Recommend single or multiple topical agents for treating plaque psoriasis given a patient’s disease presentation, severity, and (if applicable) prior therapies.
• Effectively educate a patient on an infestation and the purpose, proper use, and potential adverse reactions of the first-line treatment options for scabies and/or lice.
• Create a pain management strategy for a patient with first-degree or superficial second-degree burns.
• Create a monitoring plan for a patient using becaplermin for the treatment and healing of a decubitus ulcer.
Policy, Practice, and Regulatory Issues
ACPE # 0217-9999-19-069-H01-P

- List the congressional committees and government agencies that regulate health care in the United States.
- Identify the regulatory and oversight bodies with jurisdiction over health system delivery of care.
- Explain recent federal legislative and regulatory activity that affects the delivery of health care.
- Describe the regulatory actions that govern the prescription drug approval process and the conduct of human subjects research.
- Describe national quality initiatives aimed at improving health care delivery and patient health outcomes.
- Explain medication policy implications at an institutional level.

Faculty

Katie E. Cardone, Pharm.D., FNKF, BCACP
Associate Professor
Albany College of Pharmacy and Health Sciences
Albany, New York

Erica Crannage, Pharm.D., BCPS, BCACP
Associate Professor
St. Louis College of Pharmacy;
Clinical Pharmacist
St. Louis University Family and Community Medicine
St. Louis, Missouri

Spencer H. Durham, Pharm.D., BCPS, BCIDP
Assistant Clinical Professor
Department of Pharmacy Practice
Auburn University Harrison School of Pharmacy
Auburn, Alabama

Jessica Farrell, Pharm.D.
Clinical Pharmacist
The Center for Rheumatology, LLC
Albany College of Pharmacy and Health Sciences
Albany, New York

Alicia B. Forinash, Pharm.D., FCCP, BCPS, BCACP
Professor of Pharmacy Practice
St. Louis College of Pharmacy
St. Louis, Missouri

Nicole M. Hahn, Pharm.D., BCACP*
Clinical Pharmacy Specialist – Neurology
Kaiser Permanente
Denver, Colorado

Adam B. Jackson, Pharm.D., BCACP*
Clinical Pharmacy Specialist in Infectious Diseases
Pharmacy Department
Kaiser Permanente Colorado
Denver, Colorado

Michael P. Kane, Pharm.D., FCCP, BCPS, BCACP
Professor of Pharmacy Practice
Albany College of Pharmacy and Health Sciences;
Clinical Pharmacy Specialist
The Endocrine Group
Albany, New York

William A. Kehoe, Pharm.D., FCCP, BCPS
Professor of Clinical Pharmacy and Psychology
Chair of the Department of Pharmacy Practice
University of the Pacific
Stockton, California

Mary Ann Kliethermes, Pharm.D.
Vice Chair of the Ambulatory Care Department of Pharmacy
Practice
Associate Professor
Chicago College of Pharmacy
Midwestern University
Downers Grove, Illinois

Joel C. Marrs, Pharm.D., BCACP, BCPS-AQ Cardiology,
CLS, ASH-CHC, FASHP, FCCP, FNLA
Associate Professor
Department of Clinical Pharmacy University of Colorado
Skaggs School of Pharmacy and Pharmaceutical Sciences
Aurora, Colorado

Michelle T. Martin, Pharm.D., BCPS, BCACP
Clinical Pharmacist and Assistant Professor
University of Illinois at Chicago
Chicago, Illinois

Jamie L. McConaha, Pharm.D., BCACP*
Assistant Professor of Pharmacy Practice
Mylan School of Pharmacy Clinical, Social, and Administrative Sciences
Duquesne University
Pittsburgh, Pennsylvania

Emily McCoy, Pharm.D., BCACP
Associate Clinical Professor
Auburn University Harrison School of Pharmacy
Mobile, Alabama
Ambulatory Care Pharmacy Specialty Review
Course for Recertification

Jean Y. Moon, Pharm.D., BCACP
Assistant Professor
North Memorial Family Medicine Residency Program
College of Pharmacy
University of Minnesota
Minneapolis, Minnesota

Tiffany Scott-Horton, Pharm.D., BCACP
Clinical Assistant Professor, Pharmacy Practice;
MTMC Operations Coordinator
Ambulatory Pharmacy Services
University of Illinois at Chicago
Chicago, Illinois

Katie Suda, Pharm.D., M.S.
Associate Professor
Pharmacy Systems, Outcomes and Policy
Center Affiliate
Center for Pharmacoepidemiology and
Pharmacoeconomic Research
University of Illinois
Chicago, Illinois

Jessica Tilton, Pharm.D., BCACP
Clinical Assistant Professor
Clinical Pharmacist
Medication Therapy Management Clinic;
Operations Manager
University of Illinois at Chicago
Chicago, Illinois

Kristin Zimmerman, Pharm.D.
Associate Professor
Department of Pharmacotherapy and Outcomes Science
Virginia Commonwealth University School of Pharmacy
Richmond, Virginia

*Content Matter Experts

Acknowledgments

Jacquelyn L. Bainbridge, Pharm.D., FCCP
Professor
Department of Clinical Pharmacy
Department of Neurology in the School of Medicine
University of Colorado Denver
Aurora, Colorado

Sally Y. Barbour, Pharm.D., BCOP, CPP
Clinical Oncology Pharmacist
Duke Comprehensive Cancer Center
Duke University Medical Center
Durham, North Carolina

Ashley Branham, Pharm.D., BCACP
Director of Clinical Services
Moose Pharmacy
Concord, North Carolina

Katie E. Cardone, Pharm.D., FNKF, BCACP
Associate Professor
Albany College of Pharmacy and Health Sciences
Albany, New York

Mariann D. Churchwell, Pharm.D., BCPS
Associate Professor
University of Toledo College of Pharmacy
Toledo, Ohio

Nathan Clark, Pharm.D., FCCP, BCPS, CACP
Supervisor
Clinical Pharmacy Anticoagulation and Anemia Services
Kaiser Permanente Colorado
Aurora, Colorado

Elizabeth A. Coyle, Pharm.D., FCCM, BCPS
Clinical Associate Professor of Infectious Diseases
University of Houston College of Pharmacy;
Director of the Infectious Diseases Pharmacy Residency
University of Texas MD Anderson Cancer Center
Houston, Texas

Erica Crannage, Pharm.D., BCPS, BCACP
Associate Professor
St. Louis College of Pharmacy;
Clinical Pharmacist
St. Louis University Family and Community Medicine
St. Louis, Missouri

L. Brian Cross, Pharm.D., BCACP, CDE
Associate Professor
Gatton School of Pharmacy
East Tennessee State University
Mountain Home, Tennessee

Spencer H. Durham, Pharm.D., BCPS, BCIDP
Assistant Clinical Professor
Department of Pharmacy Practice
Auburn University Harrison School of Pharmacy
Auburn, Alabama

Jessica Farrell, Pharm.D.
Clinical Pharmacist
The Center for Rheumatology, LLC
Albany College of Pharmacy and Health Sciences
Albany, New York
Edward F. Foote, Pharm.D., FCCP, BCPS
Professor and Chair of Pharmacy Practice
Nesbitt College of Pharmacy and Nursing
Wilkes University
Wilkes-Barre, Pennsylvania

Alicia B. Forinash, Pharm.D., BCPS, BCACP
Professor of Pharmacy Practice
St. Louis College of Pharmacy
St. Louis, Missouri

Wendy A. Gattis Stough, Pharm.D.
Assistant Consulting Professor in Medicine
Department of Medicine
Division of Cardiology
Duke University Medical Center
Durham, North Carolina

Shellee A. Grim, Pharm.D., BCPS
Clinical Assistant Professor
University of Illinois at Chicago
Chicago, Illinois

Nicole M. Hahn, Pharm.D., BCACP
Clinical Pharmacy Specialist – Neurology
Kaiser Permanente
Denver, Colorado

Ila M. Harris, Pharm.D., FCCP, BCPS
Associate Professor
Med School
Department of Family Medicine and Community Health, University of Minnesota
Bethesda Family Medicine
St. Paul, Minnesota

Rachel M. Heilmann, Pharm.D., BCPS
Clinical Pharmacy Specialist in Primary Care
Kaiser Permanente Colorado
Denver, Colorado

Sheryl J. Herner, Pharm.D., BCPS, CPPS
Clinical Pharmacy Specialist in Medication Safety
Kaiser Permanente Colorado
Denver, Colorado

Adam B. Jackson, Pharm.D., BCACP
Clinical Pharmacy Specialist in Infectious Diseases
Pharmacy Department
Kaiser Permanente Colorado
Denver, Colorado

Samuel G. Johnson, Pharm.D., FCCP, BCPS-AQ, Cardiology
Clinical Pharmacy Specialist – Cardiology
Kaiser Permanente Colorado Region
Denver, Colorado

Tiffany E. Kaiser, Pharm.D., FCCP, BCPS
Associate Professor of Medicine
Assistant Director of the PGY2 Transplant Specialty Residency
University of Cincinnati Medical Center
Cincinnati, Ohio

Michael P. Kane, Pharm.D., FCCP, BCPS
Professor of Pharmacy Practice
Albany College of Pharmacy and Health Sciences
Clinical Pharmacy Specialist
The Endocrine Group
Albany, New York

William A. Kehoe, Pharm.D., FCCP, BCPS
Professor of Clinical Pharmacy and Psychology
Chair of the Department of Pharmacy Practice, University of the Pacific
Stockton, California

Mary Ann Kliethermes, Pharm.D.
Vice Chair of the Ambulatory Care Department of Pharmacy Practice
Associate Professor
Chicago College of Pharmacy
Midwestern University
Downers Grove, Illinois

Sunny A. Linnebur, Pharm.D., FCCP, BCPS, CGP
Associate Professor
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
University of Colorado Anschutz Medical Campus
Aurora, Colorado

Daniel S. Longyhore, Pharm.D., BCACP
Associate Professor
Wilkes University
Wilkes-Barre, Pennsylvania; Ambulatory Care Pharmacist
St. Luke’s Hospital & Health Network
Bethlehem, Pennsylvania

Joel C. Marrs, Pharm.D., BCACP, BCPS-AQ, Cardiology, CLS, ASH-CHC, FASHP, FCCP, FNLA
Associate Professor
Department of Clinical Pharmacy University of Colorado
Skaggs School of Pharmacy and Pharmaceutical Sciences
Aurora, Colorado
Karen F. Marlowe, Pharm.D., BCPS, CPE
Assistant Dean and Associate Department Head
James T. and Anne Klein Davis Endowed Professor
Harrison School of Pharmacy
Auburn University
Mobile, Alabama

Michelle T. Martin, Pharm.D., BCPS, BCACP
Clinical Pharmacist and Assistant Professor
University of Illinois at Chicago
Chicago, Illinois

Jamie L. McConaha, Pharm.D., BCACP
Assistant Professor of Pharmacy Practice
Mylan School of Pharmacy Clinical, Social, and Administrative Sciences
Duquesne University
Pittsburgh, Pennsylvania

Karen J. McConnell, Pharm.D., FCCP, BCPS-AQ, Cardiology
Clinical Pharmacy Specialist in Cardiology
Kaiser Permanente Colorado; Clinical Associate Professor
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences; Adjunct Professor of Pharmacy Practice
Regis University School of Pharmacy
Denver, Colorado

Emily McCoy, Pharm.D., BCACP
Associate Clinical Professor
Auburn University Harrison School of Pharmacy
Mobile, Alabama

Jean Y. Moon, Pharm.D., BCACP
Assistant Professor
North Memorial Family Medicine Residency Program,
College of Pharmacy
University of Minnesota
Minneapolis, Minnesota

Bruce A. Mueller, Pharm.D., FCCP
Professor of Pharmacy and Chair
Department of Clinical, Social and Administrative Sciences
College of Pharmacy
University of Michigan; Pharmacy Assistant Director
Department of Pharmacy Services
University Hospital
University of Michigan Health Systems
Ann Arbor, Michigan

Edith A. Nutescu, Pharm.D., FCCP
Director of the Antithrombosis Service
Associate Professor
Department of Pharmacy Practice
University of Illinois at Chicago
Chicago, Illinois

Carol A. Ott, Pharm.D., BCPP
Clinical Associate Professor of Pharmacy Practice
College of Pharmacy
Purdue University; Clinical Pharmacy Specialist in Psychiatry
Wishard Health Services and Midtown Community Mental Health
Indianapolis, Indiana

Ann M. Philbrick, Pharm.D., BCPS, BCACP
Associate Professor
University of Minnesota; Clinical Pharmacist
Bethesda Family Medicine
St. Paul, Minnesota

Theresa Prosser, Pharm.D., FCCP, BCPS
Professor
St. Louis College of Pharmacy
St. Louis, Missouri

Frank Romanelli, Pharm.D., MPH, BCPS
Associate Dean
Professor of Pharmacy, Health Sciences, and Medicine
University of Kentucky
Lexington, Kentucky

J. Mark Ruscin, Pharm.D., BCPS
Professor
Department of Pharmacy Practice
Southern Illinois University Edwardsville
Edwardsville, Illinois

Wendy L. St. Peter, Pharm.D., FCCP, FASN, FNKF, BCPS
Professor
College of Pharmacy
University of Minnesota
United States Renal Data System & Chronic Disease Research Group
Minneapolis, Minnesota

Sarah L. Scarpace, Pharm.D., BCOP
Associate Professor and Assistant Dean for Pharmacy Professional Affairs
Albany College of Pharmacy and Health Sciences; Clinical Pharmacy Specialist
Stratton Veterans’ Affairs Medical Center
Albany, New York
Tiffany Scott-Horton, Pharm.D., BCACP  
Clinical Assistant Professor, Pharmacy Practice; MTMC  
Operations Coordinator  
Ambulatory Pharmacy Services  
University of Illinois at Chicago  
Chicago, Illinois

Mansi Shah, Pharm.D., BCACP, CDE  
Assistant Professor  
University of Illinois at Chicago  
College of Pharmacy  
Chicago, Illinois

Kevin M. Sowinski, Pharm.D., FCCP  
Professor of Pharmacy Practice  
Purdue University College of Pharmacy; Adjunct Professor of Medicine  
Indiana University School of Medicine  
Indianapolis, Indiana

Sarah A. Spinler, Pharm.D., FCCP, BCPS  
Professor of Clinical Pharmacy  
Department of Pharmacy Practice and Pharmacy Administration  
Philadelphia College of Pharmacy  
University of the Sciences  
Philadelphia, Pennsylvania

Katie Suda, Pharm.D., M.S.  
Associate Professor  
Pharmacy Systems, Outcomes and Policy Center Affiliate  
Center for Pharmacoepidemiology and Pharmacoeconomic Research  
University of Illinois  
Chicago, Illinois

Michael C. Thomas, Pharm.D., BCPS  
Clinical Associate Professor and Vice Chair  
Department of Pharmacy Practice  
Western New England University  
College of Pharmacy  
Springfield, Massachusetts

Jessica Tilton, Pharm.D., BCACP  
Clinical Assistant Professor and Clinical Pharmacist  
Medication Therapy Management Clinic; Operations Manager  
University of Illinois at Chicago  
Chicago, Illinois

Andrea N. Traina, Pharm.D., BCPS, BCACP  
Assistant Professor of Pharmacy Practice  
St. John Fisher College  
Wegmans School of Pharmacy; Clinical Pharmacy Specialist  
Endocrine-Diabetes Care and Resource Center  
Rochester General Health System  
Rochester, New York

Joseph P. Vande Griend, Pharm.D., BCPS, CGP  
Assistant Professor  
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences  
Aurora, Colorado

Orly Vardeny, Pharm.D., BCACP  
Associate Professor of Pharmacy  
University of Minnesota  
Minneapolis, Minnesota

Anna Vaysman, Pharm.D., BCPS  
Clinical Assistant Professor  
University of Illinois at Chicago  
College of Pharmacy  
Chicago, Illinois

Daniel M. Witt, Pharm.D., FCCP, BCPS  
Sr. Manager Clinical Pharmacy Research & Applied Pharmacogenomics  
Kaiser Permanente Central Support Services – Pharmacy Administration  
Kaiser Permanente  
Aurora, Colorado

Pei Shieen Wong, Pharm.D., BCPS  
Neurology Clinical Research Fellow  
Department of Clinical Pharmacy  
Department of Neurology in the School of Medicine  
University of Colorado Denver  
Aurora, Colorado

Kristin Zimmerman, Pharm.D.  
Associate Professor  
Department of Pharmacotherapy and Outcomes Science  
Virginia Commonwealth University School of Pharmacy  
Richmond, Virginia
Reviewers

The American College of Clinical Pharmacy and the American Society of Health-System Pharmacists, and the authors would like to thank the following individuals for their review of Ambulatory Care Pharmacy Preparatory Review and Recertification Course.

Jamie N. Brown, Pharm.D., BCPS, BCACP
PGY2 Drug Information Residency Program Director
Drug Information/Investigational Drug Service Manager
Durham VA Medical Center
Durham, North Carolina

Rebecca M. Castner, Pharm.D., BCACP, AAHIVP
Clinical Assistant Professor, Ambulatory Care
Oregon State University/Oregon Health & Science University College of Pharmacy;
Clinical Pharmacist, Ambulatory Care
OHSU Family Medicine at Richmond
Portland, Oregon

Elizabeth A. Cook, Pharm.D., AE-C, BCACP, CDE
Clinical Assistant Professor
The University of Texas at Tyler
Ben and Maytee Fisch College of Pharmacy
Tyler, Texas

Stephanie M. (Seaton) Crist, Pharm.D., BCACP, BCGP
Assistant Professor of Pharmacy Practice, Division of Ambulatory Care
St. Louis College of Pharmacy; Clinical Pharmacy Specialist, Geriatrics
Mercy Internal Medicine Clinic
St. Louis, Missouri

Travis B. Dick, Pharm.D., M.B.A.
Assistant Professor, Department of Public Health Services
University of Rochester Medical Center
Rochester, New York

Kendra Frassetto, Pharm.D, BCACP
Clinical Pharmacy Specialist
UC Health
Cincinnati, Ohio

Timothy D. Gladwell, Pharm.D, BCPS, BCACP
Associate Dean for Academic Affairs and Assessment
University of Maryland Eastern Shore
School of Pharmacy and Health Professions
Princess Anne, Maryland

Justinne Guyton, Pharm.D., BCACP
Assistant Professor of Pharmacy Practice
Director, PGY1 Pharmacy Residency Program
Director, PGY2 Ambulatory Care Residency Program
St. Louis College of Pharmacy
St. Louis, Missouri

Randy C. Hatton, BPharm, Pharm.D., FCCP, BCPS
Clinical Professor and Program Director for MS in Patient Safety in Medication Use
UF College of Pharmacy
CEO, Professional Data Health, Inc
Newberry, Florida

Jeremy L. Johnson, Pharm.D., BCACP, CDE, BC-ADM
Assistant Professor
Department of Pharmacy Practice
Southwestern Oklahoma State University
College of Pharmacy; Clinical Pharmacist
OSU Physicians
Houston Center
Tulsa, Oklahoma

Cody Moore, Pharm.D., BCPS
Lung Transplant Clinical Pharmacist
Cystic Fibrosis Clinical Pharmacist
UPMC Presbyterian Shadyside Hospital
Pittsburgh, Pennsylvania

Stephanie Nichols, Pharm.D., BCPS, BCPP, FCCP
Associate Professor of Pharmacy Practice
School of Pharmacy
Husson University
Bangor, Maine

Lalita Prasad-Reddy, Pharm.D., M.S., BCPS, BCACP
Clinical Pharmacist - Ambulatory Care
Rush University Internists
Chicago, Illinois

Terry Richardson, Pharm.D., BCACP
Manager Pharmacy Programs, Medication Use Management
Academy of Managed Care Pharmacy
Seattle, Washington

Kelsey Rife, Pharm.D., BCACP
Hepatitis C Clinical Pharmacist
Louis Stokes VA Medical Center
Cleveland, Ohio

Sneha Baxi Srivastava, Pharm.D., BCACP, CDE
Associate Professor, Department of Pharmacy Practice
Rosalind Franklin University of Medicine and Science
North Chicago, Illinois
Disclosures
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, American College of Clinical Pharmacy and American Society of Health-System Pharmacists require that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content.

All faculty and planners for ASHP education activities are qualified and selected by ASHP and ACCP and required to disclose any relevant financial relationships with commercial interests. ASHP identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

Faculty Disclosures

- **Consultant/Member of Advisory Board**: Katie E. Cardone (AstraZeneca) Michael P. Kane (Wolters Kluwer), Michelle T. Martin (AbbVie and Gilead)
- **Grant Funding/Research Support**: Michelle T. Martin (Gilead)
- **Minor Shareholder**: Michelle T. Martin (AbbVie, Gilead, and Merck)
- **Employer**: Katie E. Cardone (Spouse employed by Fresenius Medical Care)
- **Other**: Alicia B. Forinash (royalties from Wolters Kluwer), Mary Ann Kliethermes (co-owner of Clinical Pharmacy Systems)
- **Nothing to Disclose**: Erica Crannage, Spencer H. Durham, Jessica Farrell, Nicole M. Hahn, Adam B. Jackson, William A. Kehoe, Joel C. Marrs, Emily McCoy, Jean Y. Moon, Tiffany Scott-Horton, Katie J. Suda, Jessica Tilton, Kristin Zimmerman

Reviewer Disclosures

- **Employee of Company**: Terry Richardson (Academy of Managed Care Pharmacy)
  Reviewers not listed above have nothing to disclose.

Methods and CE Requirements
Activities can be completed in any order. Each activity consists of audio, video, and/or PDFs and evaluations. Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity.

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.
System Technical Requirements
Learning activities are delivered via your Web browser and Acrobat PDF. For all activities you should have a basic comfort level using a computer and navigating web sites.

View the minimum technical and system requirements for learning activities.

Development
These activities were developed by ASHP and ACCP.